Researchers from King’s College London and McMaster University in Canada have reported encouraging preclinical results using a form of immunotherapy to treat glioblastoma, an aggressive and often fatal type of brain cancer. Glioblastoma patients typically face a median survival of just 12 to 18 months following diagnosis, highlighting an urgent need for more effective therapies.

The new study focuses on chimeric antigen receptor T-cell therapy, commonly known as CAR-T. This approach involves genetically modifying a patient’s own immune cells to better identify and attack cancerous cells. Using laboratory models designed to closely mimic human glioblastoma, the team found that CAR-T treatment was capable of eliminating tumors and suggested potential for long-term, disease-free survival.

Sheila Singh, a professor specializing in neuro-oncology and neurosurgery at both institutions, explained a key obstacle addressed by the therapy. According to Singh, a significant portion of glioblastoma tumors comprises immune cells called macrophages. While macrophages generally play a protective role in fighting infections, glioblastoma tumors can manipulate and reprogram these cells to facilitate tumor growth, evade immune detection, and resist treatments.

The findings offer a promising avenue for improving outcomes in glioblastoma, a cancer type that has historically shown resistance to conventional therapies such as chemotherapy and radiation. While these results are preliminary and derived from experimental models rather than clinical trials, they provide a foundation for further investigation into CAR-T therapies as a potential treatment option for this challenging disease.